References
- Alvarez FP, Chevalier P, Borms M, et al. Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal. J Med Econ. 2023;26(1):710–719. doi:10.1080/13696998.2023.2194193.
- Alvarez FP, Petitjean A, Nealon J, et al. Cost-effectiveness analysis has to consider all available evidence when informing inputs. Hum Vaccin Immunother. 2021;17(3):694–695. doi:10.1080/21645515.2020.1799670.
- Hadigal S, Colombo L, Cook J. Reply letter to “cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal”. J Med Econ. 2023;26(1):933–934. doi:10.1080/13696998.2023.2237379.
- Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018;17(5):435–443. doi:10.1080/14760584.2018.1471989.
- Heads of Medicines Agencies. 2020. Public assessment report. Efluelda, suspension for injection in pre-filled syringe. Available at https://mri.cts-mrp.eu/portal/details?productnumber=NL/H/4757/001. (accessed June 2023)
- Somes MP, Turner RM, Dwyer LJ, et al. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: a systematic review and meta-analysis. Vaccine. 2018;36(23):3199–3207. doi:10.1016/j.vaccine.2018.04.063.
- World Health Organization. 2015. A manual for estimating disease burden associated with seasonal influenza. World Health Organization. https://apps.who.int/iris/handle/10665/178801., accessed June 2023.